Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation - PubMed

Affiliations

• PMID: 30325245
• DOI: 10.1080/17512433.2018.1536544

Review

Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation

Carlo Bastianelli et al. Expert Rev Clin Pharmacol. 2018 Nov.

Abstract

Following a historical overview, the ovulation-inhibiting effect of various orally administered estrogen-progestin combinations (combined oral contraceptives [COCs]) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Inhibition of ovulation with progestins alone; estrogens alone; various progestins in combination with ethinyl estradiol; various progestins in combination with natural estrogens (estradiol, estradiol valerate, and estetrol). Expert commentary: The original idea to achieve ovulation blockage through the administration of steroid hormones involved the use a progestogen (both progesterone and its synthetic homologous). The ability of a progestin to inhibit ovulation depends on the type of compound and on its dosage and a difference of more than 20-fold in activity exists between compounds utilized today in COCs. Initially, the estrogenic component was present only because it contaminated the first progestin utilized. It was soon found that an estrogen is necessary for proper cycle control. It was also found that the estrogen acts synergistically in inhibiting ovulation. For almost half a century, most COCs contained ethinyl estradiol. Today, also natural estrogens are being employed. Inhibition of ovulation was complete with all early high dose preparations. Decreasing dosage allowed some ovarian activity to occur, occasionally leading to a mature follicle. Even in this situation, defective corpus luteum formation assured contraceptive protection.

Keywords: Androgens; combined oral contraceptives; drospirenone; estradiol; estradiol valerate; estrogens; ethinyl estradiol; hemostasis; nomegestrol acetate; progestins.

Similar articles

• Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.

  Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Farris M, et al. Expert Rev Clin Pharmacol. 2017 Oct;10(10):1129-1144. doi: 10.1080/17512433.2017.1356718. Epub 2017 Aug 7. Expert Rev Clin Pharmacol. 2017. PMID: 28712325 Review.

• Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.

  Stanczyk FZ, Archer DF, Bhavnani BR. Stanczyk FZ, et al. Contraception. 2013 Jun;87(6):706-27. doi: 10.1016/j.contraception.2012.12.011. Epub 2013 Jan 8. Contraception. 2013. PMID: 23375353 Review.

• Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide.

  Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. Endrikat J, et al. Contraception. 2011 Dec;84(6):549-57. doi: 10.1016/j.contraception.2011.04.009. Epub 2011 Jun 8. Contraception. 2011. PMID: 22078182 Review.

• Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism.

  Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G. Bastianelli C, et al. Expert Rev Clin Pharmacol. 2017 Mar;10(3):315-326. doi: 10.1080/17512433.2017.1271708. Epub 2017 Jan 11. Expert Rev Clin Pharmacol. 2017. PMID: 27977304 Review.

• Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.

  Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Wahl P, et al. N Engl J Med. 1983 Apr 14;308(15):862-7. doi: 10.1056/NEJM198304143081502. N Engl J Med. 1983. PMID: 6572785

Cited by

• Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view.

  James AH. James AH. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):148-151. doi: 10.1182/hematology.2019000071. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808870 Free PMC article.

• The attention-emotion interaction in healthy female participants on oral contraceptives during 1-week escitalopram intake.

  Beinhölzl N, Molloy EN, Zsido RG, Richter T, Piecha FA, Zheleva G, Scharrer U, Regenthal R, Villringer A, Okon-Singer H, Sacher J. Beinhölzl N, et al. Front Neurosci. 2022 Sep 9;16:809269. doi: 10.3389/fnins.2022.809269. eCollection 2022. Front Neurosci. 2022. PMID: 36161146 Free PMC article.

• Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review.

  Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, Witchel S, Pena A, Mousa A, Teede H. Forslund M, et al. Clin Endocrinol (Oxf). 2023 Jul;99(1):79-91. doi: 10.1111/cen.14913. Epub 2023 Mar 27. Clin Endocrinol (Oxf). 2023. PMID: 36939017 Free PMC article.

• Estetrol/Drospirenone: A Review in Oral Contraception.

  Lee A, Syed YY. Lee A, et al. Drugs. 2022 Jul;82(10):1117-1125. doi: 10.1007/s40265-022-01738-8. Epub 2022 Jul 4. Drugs. 2022. PMID: 35781795 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon